Daré Bioscience (NASDAQ:DARE) Rating Lowered to Hold at Brookline Capital Management

Brookline Capital Management downgraded shares of Daré Bioscience (NASDAQ:DARE) from a buy rating to a hold rating in a research note published on Wednesday morning, Marketbeat reports.

DARE has been the topic of several other reports. HC Wainwright reissued a buy rating and issued a $6.00 price objective on shares of Daré Bioscience in a research report on Monday, April 1st. Dawson James downgraded shares of Daré Bioscience from a buy rating to a neutral rating in a research note on Tuesday, January 30th.

Daré Bioscience Price Performance

Shares of DARE opened at $0.28 on Wednesday. The firm has a market capitalization of $28.16 million, a PE ratio of -0.82 and a beta of 1.16. The company’s 50-day moving average is $0.46 and its 200-day moving average is $0.40. Daré Bioscience has a fifty-two week low of $0.27 and a fifty-two week high of $1.10.

Institutional Investors Weigh In On Daré Bioscience

A number of hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in shares of Daré Bioscience in the 3rd quarter valued at approximately $2,988,000. Vanguard Group Inc. boosted its stake in shares of Daré Bioscience by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,533,563 shares of the biotechnology company’s stock valued at $3,533,000 after purchasing an additional 30,299 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Daré Bioscience by 26.3% in the 2nd quarter. Renaissance Technologies LLC now owns 718,821 shares of the biotechnology company’s stock valued at $654,000 after purchasing an additional 149,762 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Daré Bioscience by 63.7% in the 1st quarter. BlackRock Inc. now owns 602,036 shares of the biotechnology company’s stock valued at $897,000 after purchasing an additional 234,243 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Daré Bioscience by 73.9% in the 2nd quarter. Millennium Management LLC now owns 445,086 shares of the biotechnology company’s stock valued at $547,000 after purchasing an additional 189,091 shares in the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.